Last updated: May 30, 2026
Danicopan is a small-molecule C3/C3b inhibitor under clinical development (Immunology; complement). Public procurement, contract manufacturing, and upstream API supply information is not fully determinable from available open sources in a way that supports a complete, defensible supplier list.
Which companies supply danicopan drug substance (API) and drug product?
No complete, source-citable roster of danicopan API and formulated drug product suppliers is publicly confirmed in a way that supports an “all suppliers” answer.
What to check in diligence packages (to identify danicopan suppliers fast)
Because danicopan is a clinical-stage program, supplier discovery typically comes from the following documents and databases:
- Clinical trial materials: site packaging inserts, investigator brochures, and lot-specific labels (often show manufacturer of record for IMP).
- CMC sections in regulatory filings: manufacturing sites and contract roles for drug substance and drug product.
- Contract manufacturing disclosures: licensing agreements and technology transfer documentation for oral solid dose development.
What suppliers appear in danicopan clinical trial materials?
Open, comprehensive labeling-level supplier data for danicopan across global trials is not available in a single consolidated, source-citable list.
Where supplier names usually surface for danicopan
- IMP labels on blinded kits (manufacturer of record, packager/labeler, and sometimes API site).
- Safety data sheets (SDS) for investigational material, which can list manufacturer/distributor and sometimes the producer.
- Clinical protocols and amendments for manufacturing changes, including site transfers and scale-up.
Are there danicopan CDMOs for oral solid dose manufacturing?
No confirmed, fully sourced set of danicopan CDMOs for oral solid dose drug product is publicly available in a way that supports specific naming.
Key CDMO diligence points for danicopan sourcing
- Dry powder handling and particle engineering requirements (if formulation includes solubilization or absorption enhancement).
- Analytical release testing coverage: impurity profiling, residual solvents, polymorph/solid-state control.
- Stability program: temperature, humidity, and forced degradation data tied to manufacturing site.
Which suppliers handle packaging, labeling, and distribution for danicopan clinical supply?
A consolidated supplier list for clinical packaging, labeling, and distribution is not available in source-citable form.
What “supply chain” roles to map for danicopan
- IMP manufacturing site (drug product).
- Labeling and secondary packaging.
- Global distribution partner (clinical supply logistics).
- Storage and cold-chain requirements (if any).
What contract manufacturing risks exist if you source danicopan for research?
For clinical-stage molecules like danicopan, the main supply risks are typically not commercial (price) but CMC and authorization.
Typical sourcing barriers to watch
- Limited authorized suppliers due to IMP control and lot traceability.
- Batch-specific analytical specifications and stability commitments.
- Transfer constraints if you need additional testing or a different comparator format.
What generic or biosimilar supply chain is relevant for danicopan?
Danicopan has no approved generic or biosimilar supply chain. Any “supplier” list is instead limited to clinical supply for investigational material.
How does danicopan compare with other complement inhibitors on supplier transparency?
Complement small molecules in clinical development often show incomplete public supplier visibility until later-stage filings.
Practical implication for supplier mapping
If you need supplier names for danicopan today, the highest-yield path is to extract them from lot labels, SDS documents, and CMC manufacturing site disclosures in regulatory submissions, rather than relying on public vendor directories.
Key Takeaways
- Danicopan supplier identification (API and drug product) cannot be completed with a defensible, source-citable list from publicly available consolidated information.
- Supplier names for danicopan typically emerge from IMP labeling, SDS, and CMC disclosures rather than from market-facing procurement data.
- Diligence should focus on lot traceability, manufacturing site roles (API vs formulated product vs packaging), and the control strategy used for investigational material.
FAQs
-
Where can danicopan manufacturing site names be found for clinical supply?
On IMP labels, safety data sheets, and CMC/regulatory documentation tied to clinical lots.
-
Who typically acts as contract manufacturer for complement inhibitor investigational drugs like danicopan?
Contract manufacturing organizations (CDMOs) for oral solid dose drug product and separate CDMO sites for drug substance, with roles documented in CMC sections and trial lot documentation.
-
Can a generic supplier legally sell danicopan for research use today?
Danicopan is investigational; availability is generally limited to authorized research supply channels and approved-compliance distribution.
-
What documents should procurement teams request to verify danicopan supply chain integrity?
SDS, CoA for specific lots, GMP manufacturing site documentation, and chain-of-custody records for clinical materials.
-
How do you reduce batch-to-batch risk when sourcing investigational danicopan?
Require lot-specific CoAs, confirm specifications for impurities/solvents/solid state, and align storage and stability conditions to the receiving lab’s testing plan.
References (APA)
- Not enough source-citable material is available in the prompt context to support a supplier list for danicopan.
